FDA approves combination treatment for melanoma.
Reuters (1/9, Hirschler) reports that the FDA has granted accelerated approval to a combination treatment for melanoma offered by GlaxoSmithKline. According to the article, both dabrafenib and trametinib are approved for treatment of melanoma, but GSK believes they will last longer when given together.